ProKidney to Join Major Healthcare Conference
ProKidney Corp. (Nasdaq: PROK), a prominent late clinical-stage biotech firm focused on cell therapy for chronic kidney disease (CKD), has announced that its senior management will take part in the Morgan Stanley 22nd Annual Global Healthcare Conference. This important event is scheduled to occur from September 4 to September 6, 2024.
Details on Conference Participation
At the conference, ProKidney's management team will discuss the company's progress and the potential effects of their innovative therapies on CKD management. A key highlight will be a fireside chat set for September 5, 2024, at 7:00 a.m. ET.
Live Webcast Availability
Those interested can access the live webcast of the event in the 'Events' section under the Investor Relations tab on ProKidney's official website. After the fireside chat, a replay of the webcast will be available for 90 days, allowing a wider audience to gain insights and updates.
One-on-One Investor Meetings
In addition to group presentations, ProKidney's management will conduct one-on-one meetings with interested investors during the conference. Investors who wish to schedule a meeting are encouraged to connect with their Morgan Stanley representatives.
About ProKidney Corp.
Established in 2015, ProKidney is known for its groundbreaking efforts in treating chronic kidney disease through advanced cellular therapies. The company's leading candidate, rilparencel, also referred to as REACT, represents a significant advancement in autologous cellular therapy aimed at maintaining kidney function in patients suffering from diabetes and advanced CKD. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation and guidance from major regulatory authorities like the FDA and EMA, underscoring its ongoing Phase 3 clinical program.
Investor Contact Information
For questions related to investment opportunities and participation in the conference, interested individuals may reach out to:
ProKidney
Ethan Holdaway
Email: Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Email: Daniel@lifesciadvisors.com
Frequently Asked Questions
What is the significance of ProKidney's participation in the conference?
ProKidney's involvement underscores their dedication to sharing advancements in therapies for chronic kidney disease with potential investors and stakeholders.
Where can I access the live webcast during the conference?
You can find the live webcast on ProKidney's official website under the Investor Relations section.
What is rilparencel and why is it important?
Rilparencel, also known as REACT, is a patented autologous therapy currently in clinical trials designed to help preserve kidney function in patients with diabetes and advanced CKD.
How can investors arrange one-on-one meetings?
Investors interested in scheduling one-on-one meetings should reach out to their Morgan Stanley representatives for further details.
How long will the replay of the webcast be available after the event?
The replay of the webcast will be accessible for 90 days following the initial broadcast.